Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening
- ACS Pharmacol Transl Sci. 2024 Mar 21;7(4):1086-1100. doi: 10.1021/acsptsci.3c00378.
- 1. Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
- 2. Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
- 3. Warren Center for Neuroscience Drug Discovery, Nashville, Tennessee 37067, United States.
- 4. Institute for Drug Discovery, Leipzig University Medical School, Leipzig 04109, Germany.
- 5. Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94158, United States.
Here, we demonstrate a structure-based small molecule virtual screening and lead optimization pipeline using a homology model of a difficult-to-drug G-protein-coupled receptor (GPCR) target. Protease-activated Receptor 4 (PAR4) is activated by Thrombin cleavage, revealing a tethered ligand that activates the receptor, making PAR4 a challenging target. A virtual screen of a make-on-demand chemical library yielded a one-hit compound. From the single-hit compound, we developed a novel series of PAR4 antagonists. Subsequent lead optimization via simultaneous virtual library searches and structure-based rational design efforts led to potent antagonists of thrombin-induced activation. Interestingly, this series of antagonists was active against PAR4 activation by the native protease Thrombin cleavage but not the synthetic PAR4 Agonist peptide AYPGKF.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Inflammation/Immunology
-
Research Areas: Cardiovascular Disease